Freedland SJ - Search Results

1

Castration-resistant prostate cancer: AUA Guideline.

Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Cookson MS, et al. Among authors: freedland sj. J Urol. 2013 Aug;190(2):429-38. doi: 10.1016/j.juro.2013.05.005. Epub 2013 May 9. J Urol. 2013. PMID: 23665272

2

Immunotherapy of prostate cancer.

Freedland SJ, Pantuck AJ, Weider J, Zisman A, Belldegrun AS. Freedland SJ, et al. Curr Urol Rep. 2001 Jun;2(3):242-7. doi: 10.1007/s11934-001-0086-9. Curr Urol Rep. 2001. PMID: 12084272 Review.

3

Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.

Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Aronson WJ; Search Database Study Group. Freedland SJ, et al. J Urol. 2004 Jun;171(6 Pt 1):2215-20. doi: 10.1097/01.ju.0000124463.13319.0a. J Urol. 2004. PMID: 15126788

4

Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.

Freedland SJ, Mangold LA, Epstein JI, Partin AW. Freedland SJ, et al. Urology. 2004 May;63(5):887-91. doi: 10.1016/j.urology.2003.11.032. Urology. 2004. PMID: 15134972

5

Serum leptin and pathological findings at the time of radical prostatectomy.

Freedland SJ, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, Partin AW. Freedland SJ, et al. J Urol. 2005 Mar;173(3):773-6. doi: 10.1097/01.ju.0000152619.96795.b2. J Urol. 2005. PMID: 15711267

6

Obesity and prostate cancer.

Freedland SJ, Aronson WJ. Freedland SJ, et al. Urology. 2005 Mar;65(3):433-9. doi: 10.1016/j.urology.2004.08.035. Urology. 2005. PMID: 15780350 Review. No abstract available.

7

Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.

Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ. Makarov DV, et al. Among authors: freedland sj. J Urol. 2006 Aug;176(2):554-8. doi: 10.1016/j.juro.2006.03.058. J Urol. 2006. PMID: 16813888

8

Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Freedland SJ, et al. J Urol. 2006 Oct;176(4 Pt 1):1404-8. doi: 10.1016/j.juro.2006.06.017. J Urol. 2006. PMID: 16952644

9

Prostate specific antigen recurrence after definitive therapy.

Freedland SJ, Moul JW. Freedland SJ, et al. J Urol. 2007 Jun;177(6):1985-91. doi: 10.1016/j.juro.2007.01.137. J Urol. 2007. PMID: 17509277 Review.

10

A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database.

Fitzsimons NJ, Sun LL, Dahm P, Moul JW, Madden J, Gan TJ, Freedland SJ. Fitzsimons NJ, et al. Among authors: freedland sj. Urology. 2007 Dec;70(6):1146-51. doi: 10.1016/j.urology.2007.07.065. Urology. 2007. PMID: 18158036

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

752 results

Search Page